Coherus to Participate in Upcoming Investor Conferences
Key Highlights
- ➤Coherus to webcast presentations at two upcoming investor conferences in November 2026
- ➤LOQTORZI remains Coherus’ approved next-generation PD-1 inhibitor
- ➤Tagmokitug is in Phase 1b/2a studies for advanced solid tumors
- ➤Casdozokitug is being evaluated in a Phase 2 first-line hepatocellular carcinoma study
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be webcasting its participation in the following upcoming investor conferences: * Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on Tuesday, November 10, 2026, at 7:30 a.m. Eastern Daylight Time. * Jefferies Global Healthcare Conference in London, UK on Monday, November 16, 2026, at 10:30 a.m. Greenwich Mountain Time / 5:30 a.m. Eastern Daylight Time The presentations will be accessible via webcast links on the Investor Events section of the Coherus website: https://investors.coherus.com/events-presentations. Replays of the presentations will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective bank representative.
Get started
Create a free account to read the full story.